Publication | Open Access

Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial

VaccinationVaccine SafetyVaccine DevelopmentOpen-label Phase 3Heterologous BoostImmunologyImmunodominanceVaccine EfficacyAerosolised Ad5-ncovMedicineVaccine ResearchCovid-19